Profile data is unavailable for this security.
About the company
Philogen SpA is an Italy-based company, operating in the biotechnology sector. The Company develops products and technologies for the diagnosis and therapy of serious human diseases. It has three anti-cancer antibody derivatives, produced with an in-house industrial process, into Phase I/II clinical studies. The majority of its technologies and products are based on high-affinity human monoclonal antibody fragments. Philogen SpA developed a patented technology, Iterative Colony Filter Screening, for the isolation of monoclonal antibodies, which requires neither immunization nor phage display. The Company's subsidiaries are Philotec, Philomed and Philochem. Philogen SpA is headquartered in Siena, Italy.
- Revenue in EUR (TTM)23.13m
- Net income in EUR-6.16m
- Incorporated--
- Employees160.00
- LocationPhilogen SpAVia Bellaria, 35SOVICILLE 53018ItalyITA
- Phone+39 577206941
- Fax+39 57742151
- Websitehttps://www.philogen.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medincell SA | 10.85m | -26.42m | 410.11m | 138.00 | -- | -- | -- | 37.81 | -1.02 | -1.02 | 0.4086 | -0.8965 | 0.2605 | -- | 6.81 | 75,853.15 | -63.46 | -59.54 | -115.15 | -117.36 | 60.43 | 68.38 | -243.58 | -451.26 | -- | -4.29 | 1.69 | -- | 141.78 | 8.96 | -29.04 | -- | -2.87 | -- |
| Idorsia Ltd | 142.99m | -56.50m | 415.76m | 938.00 | -- | -- | -- | 2.91 | -0.3534 | -0.3534 | 0.7363 | -4.97 | 0.1912 | 0.1645 | 113.09 | 150,766.50 | -7.56 | -46.72 | -12.46 | -53.84 | 93.05 | -- | -39.51 | -709.80 | 1.00 | -26.26 | 5.82 | -- | 56.93 | 20.25 | 64.01 | -- | -8.01 | -- |
| Nykode Therapeutics ASA | 9.77m | -36.60m | 416.67m | 176.00 | -- | 2.85 | -- | 42.66 | -1.42 | -1.42 | 0.3754 | 5.19 | 0.0534 | -- | 91.80 | 653,917.10 | -20.01 | 5.65 | -22.97 | 6.38 | -- | -- | -374.77 | 18.13 | -- | -- | 0.0313 | -- | 79.99 | 282.17 | 17.75 | -- | 187.37 | -- |
| Guerbet SA | 785.69m | 23.87m | 457.61m | 2.92k | 20.12 | 1.21 | 5.49 | 0.5824 | 1.80 | 1.80 | 62.15 | 29.97 | 0.7997 | 0.5983 | 5.80 | 269,071.90 | 2.26 | 1.40 | 2.96 | 1.86 | 78.01 | 76.02 | 2.82 | 1.82 | 1.21 | 5.62 | 0.5035 | 57.82 | 4.30 | -0.0993 | 158.05 | -12.61 | 5.23 | -10.07 |
| Pharmanutra SpA | 100.32m | 10.83m | 467.11m | 111.00 | 42.74 | 8.14 | 34.17 | 4.66 | 1.13 | 1.13 | 10.43 | 5.93 | 0.9123 | 0.5233 | 4.00 | 955,428.60 | 9.85 | 18.39 | 13.20 | 24.80 | 95.92 | 96.36 | 10.79 | 17.77 | 1.87 | 37.86 | 0.3324 | 52.51 | 21.13 | 16.51 | -14.73 | 8.44 | 75.71 | 11.20 |
| Philogen SpA | 23.13m | -6.16m | 523.45m | 160.00 | -- | 7.96 | -- | 22.63 | -0.1551 | -0.1551 | 0.5747 | 2.25 | 0.1887 | 6.65 | 7.95 | 144,562.50 | -5.03 | -7.32 | -5.56 | -8.36 | 40.04 | 32.04 | -26.64 | -58.66 | 6.84 | -- | 0.1414 | -- | -2.46 | 10.80 | -14.60 | -- | 51.78 | -- |
| Valneva SE | 152.96m | -24.39m | 529.25m | 684.00 | -- | 2.79 | 10.35 | 3.46 | -0.1943 | -0.1943 | 1.10 | 1.36 | 0.2799 | 2.34 | 5.63 | 223,622.80 | -4.46 | -15.39 | -6.84 | -25.06 | 32.95 | 35.94 | -15.95 | -34.95 | 2.22 | -2.69 | 0.528 | -- | -57.46 | 6.34 | 29.21 | -- | 35.18 | -- |
| Gen Ilac ve Saglik Urnlr Snyi ve Tcrt AS | 233.24m | 13.01m | 535.64m | 622.00 | 41.18 | 3.87 | 26.06 | 2.30 | 1.52 | 1.52 | 27.17 | 16.12 | 1.16 | 6.53 | 7.72 | 13,105,500.00 | 6.45 | 12.39 | 8.91 | 17.53 | 22.07 | 19.06 | 5.55 | 6.95 | 0.9854 | -- | 0.2095 | -- | -23.38 | 47.18 | -28.97 | 147.97 | -- | -- |
| Deva Holding AS | 218.61m | 66.04m | 546.28m | 2.93k | 8.27 | 3.29 | 7.62 | 2.50 | 11.54 | 11.54 | 38.20 | 28.97 | 0.7464 | 1.49 | 6.52 | 2,686,365.00 | 22.55 | 21.33 | 43.27 | 33.37 | 56.78 | 53.72 | 30.21 | 32.51 | 0.9899 | -- | 0.4776 | 2.77 | 92.15 | 41.11 | 16.25 | 71.18 | 58.49 | -- |
| Pharming Group N.V. | 238.03m | -9.94m | 548.57m | 415.00 | -- | 2.89 | 68.03 | 2.30 | -0.016 | -0.016 | 0.3606 | 0.2818 | 0.5976 | 0.5677 | 7.21 | 573,573.90 | -2.50 | 5.26 | -3.61 | 6.63 | 88.57 | 89.41 | -4.18 | 9.26 | 1.16 | -7.42 | 0.4481 | -- | 19.30 | 9.01 | -177.14 | -- | -13.04 | -- |
| Basilea Pharmaceutica AG Allschwil | 159.39m | 10.57m | 573.93m | 147.00 | 49.18 | -- | 47.10 | 3.60 | 0.8765 | 0.8765 | 13.15 | -0.8335 | 0.7999 | 1.06 | 5.16 | 1,072,340.00 | 5.30 | -1.86 | 7.69 | -2.99 | 83.00 | 83.45 | 6.63 | -2.99 | 2.64 | 2.02 | 1.10 | -- | 6.68 | 3.53 | -13.96 | -- | 11.17 | -- |
| Calliditas Therapeutics AB | 103.98m | -40.16m | 595.42m | 195.00 | -- | 18.60 | -- | 5.73 | -8.69 | -8.69 | 22.49 | 6.24 | 0.6332 | 5.02 | 9.30 | 6,189,175.00 | -24.46 | -26.46 | -30.27 | -30.27 | 94.99 | -- | -38.63 | -76.59 | 3.08 | -4.44 | 0.7427 | -- | 50.32 | -- | -13.08 | -- | -- | -- |
| Boiron SA | 493.25m | 35.83m | 607.07m | 2.81k | 16.77 | 1.53 | 10.97 | 1.23 | 2.06 | 2.06 | 28.41 | 22.67 | 0.715 | 1.40 | 5.26 | 175,533.10 | 4.92 | 4.59 | 6.16 | 5.76 | 72.60 | 74.02 | 6.88 | 6.80 | 1.50 | -- | 0.0338 | 53.86 | -7.67 | -3.98 | -19.80 | -9.01 | -17.68 | -1.42 |
| Surgical Science Sweden AB | 72.54m | 17.91m | 641.82m | 265.00 | 35.82 | 1.62 | 28.13 | 8.85 | 4.08 | 4.08 | 16.51 | 89.92 | 0.1749 | 1.68 | 6.12 | 3,238,531.00 | 4.32 | 4.49 | 4.59 | 4.78 | 68.59 | 70.06 | 24.70 | 23.75 | 3.53 | -- | 0.00 | 0.00 | 10.01 | 68.14 | 24.47 | -- | 38.57 | -- |
Data as of May 22 2024. Currency figures normalised to Philogen SpA's reporting currency: Euro EUR
4.79%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fideuram Asset Management SGR SpAas of 29 Apr 2024 | 558.42k | 1.91% |
| CARTHESIO SAas of 30 Jun 2023 | 220.00k | 0.75% |
| Azimut Capital Management SGR SpAas of 30 Apr 2024 | 158.23k | 0.54% |
| Mediolanum Gestione Fondi SGRpAas of 29 Dec 2023 | 133.22k | 0.46% |
| Schroder Investment Management Ltd.as of 31 Jan 2024 | 103.98k | 0.36% |
| Ersel Asset Management SGR SpAas of 30 Jun 2023 | 56.41k | 0.19% |
| AcomeA SGR SpAas of 30 Jun 2023 | 45.00k | 0.15% |
| Amundi SGR SpAas of 29 Feb 2024 | 42.87k | 0.15% |
| Kairos Partners SGR SpAas of 29 Dec 2023 | 41.06k | 0.14% |
| Aramea Asset Management AGas of 30 Jun 2022 | 40.00k | 0.14% |
More ▼
Data from 02 Nov 2023 - 30 Apr 2024Source: FactSet Research Systems Inc.
